This Diagnostics Company Is Advancing a Global Expansion Strategy, Positioning for Growth Phase
The molecular diagnostics sector continues to evolve as companies shift focus from pandemic-driven demand toward broader infectious disease testing, global distribution networks, and next-generation platforms powered by artificial intelligence. As regulatory pathways reopen and international markets expand, companies with scalable, adaptable technologies are working to reposition themselves for long-term growth.Shares of Co-Diagnostics, Inc. (NASDAQ: CODX) finished Tuesday higher after the company reported its full-year 2025 financial results and outlined progress across its global ...
AllPennyStocks.com·9h ago